1. Large animal models to study effectiveness of therapy devices in the treatment of heart failure with preserved ejection fraction (HFpEF).
- Author
-
Fisher, Shane Michael, Murally, Anjali Rosanna, Rajabally, Zahra, Almas, Talal, Azhar, Maimoona, Cheema, Faisal H., Malone, Andrew, Hasan, Babar, Aslam, Nadeem, Saidi, Jemil, O'Neill, Jim, and Hameed, Aamir
- Subjects
HEART failure ,VENTRICULAR ejection fraction ,TREATMENT failure ,ANIMAL models in research ,DRUG target - Abstract
Our understanding of the complex pathophysiology of Heart failure with preserved ejection fraction (HFpEF) is limited by the lack of a robust in vivo model. Existing in-vivo models attempt to reproduce the four main phenotypes of HFpEF; ageing, obesity, diabetes mellitus and hypertension. To date, there is no in vivo model that represents all the haemodynamic characteristics of HFpEF, and only a few have proven to be reliable for the preclinical evaluation of potentially new therapeutic targets. HFpEF accounts for 50% of all the heart failure cases and its incidence is on the rise, posing a huge economic burden on the health system. Patients with HFpEF have limited therapeutic options available. The inadequate effectiveness of current pharmaceutical therapeutics for HFpEF has prompted the development of device-based treatments that target the hemodynamic changes to reduce the symptoms of HFpEF. However, despite the potential of device-based solutions to treat HFpEF, most of these therapies are still in the developmental stage and a relevant HFpEF in vivo model will surely expedite their development process. This review article outlines the major limitations of the current large in-vivo models in use while discussing how these designs have helped in the development of therapy devices for the treatment of HFpEF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF